Pilot Study to Evaluate the Effect of Oral Supplementation of Enterococcus Faecium SF68 on Cats with Latent Feline Herpesvirus 1

2009 ◽  
Vol 11 (8) ◽  
pp. 650-654 ◽  
Author(s):  
Michael R. Lappin ◽  
Julia K. Veir ◽  
Ebenezer Satyaraj ◽  
Gail Czarnecki-Maulden
Keyword(s):  
Pilot Study ◽  
Immune Responses ◽  
Enterococcus Faecium ◽  
Clinical Signs ◽  
Clinical Results ◽  
Fecal Microbiome ◽  
Oral Supplementation ◽  
Feline Herpesvirus ◽  
Herpesvirus 1 ◽  
Faecium Strain

Feline herpesvirus 1 (FHV-1) infection is extremely common in cats and is frequently associated with morbidity because of recurrent ocular and respiratory clinical signs of disease. Enterococcus faecium strain SF68 is an immune-enhancing probiotic used as a dietary supplement. In this pilot study, 12 cats with chronic FHV-1 infection were administered either SF68 or a placebo, monitored for clinical signs of disease, monitored for FHV-1 shedding, and evaluated for FHV-1 specific humoral and cell-mediated immune responses and fecal microbiome stability. Fecal microbial diversity was maintained throughout the study in cats supplemented with SF68, but decreased in cats fed the placebo, indicating a more stable microbiome in cats fed SF68. While clinical results varied among individual cats, the overall findings suggest that administration of the probiotic lessened morbidity associated with chronic FHV-1 infection in some cats. Additional study is warranted to determine efficacy in a clinical setting.

Effect of modified live or inactivated feline herpesvirus-1 parenteral vaccines on clinical and laboratory findings following viral challenge

2016 ◽  
Vol 19 (8) ◽  
pp. 824-830 ◽  
Author(s):  
Stacie C Summers ◽  
Rebecca Ruch-Gallie ◽  
Jennifer R Hawley ◽  
Michael R Lappin
Keyword(s):  
Clinical Signs ◽  
Clinical Score ◽  
Laboratory Findings ◽  
Vaccine Product ◽  
Feline Herpesvirus ◽  
Specific Pathogen ◽  
Group 3 ◽  
Herpesvirus 1 ◽  
Group 2 ◽  
Group 1

Objectives The objective was to investigate the effect of one dose of an inactivated feline herpesvirus-1 (FHV-1), feline calicivirus (FCV) and panleukopenia virus (FPV) vaccine (FVRCP) or one dose of a modified live (ML) FVRCP vaccine on clinical signs and shedding of FHV-1 in specific pathogen-free kittens after challenge with FHV-1 7 days after vaccination. Methods Twenty-four FHV-1 seronegative 5-month-old kittens were randomized into three groups of eight kittens. Group 1 kittens were maintained as unvaccinated controls, group 2 kittens were administered one dose of the inactivated FVRCP vaccine subcutaneously (SC) and group 3 kittens were administered one dose of the ML FVRCP vaccine SC. All 24 cats were administered FHV-1 by nasal and oropharyngeal inoculation 7 days later and were observed daily for clinical signs of illness for 21 days. Results In the 21 days after FHV-1 challenge, both groups of vaccinated cats were less likely to be clinically ill (indicated by lower cumulative clinical scores) than control cats ( P <0.001). There was no statistical difference in total clinical score between the two vaccinated groups ( P = 0.97). Although the total clinical score was similar between both vaccines, signs of respiratory disease were significantly fewer in the kittens vaccinated with the inactivated FVRCP vaccine compared with the ML FVRCP vaccine ( P = 0.005) during the period after inoculation when the majority of clinical disease was observed. Conclusions and relevance Parenteral administration of either the inactivated FVRCP vaccine or the ML FVRCP vaccine can decrease clinical signs of illness due to FHV-1 on a day 7 challenge when compared with controls. Use of either vaccine product is indicated in cats at risk of acute exposure to FHV-1.

scholarly journals Variable accuracy, precision, and consistency of compounded famciclovir formulated for management of feline herpesvirus‐1 in cats

2021 ◽  
Author(s):  
Louise M. O'Leary ◽  
Rachel A. Allbaugh ◽  
Dwayne E. Schrunk ◽  
Thomas E. Olsen ◽  
Lionel Sebbag
Keyword(s):  
Feline Herpesvirus ◽  
Herpesvirus 1

scholarly journals Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy

2016 ◽  
Vol 9 (1) ◽  
Author(s):  
Takashi Matono ◽  
Kayoko Hayakawa ◽  
Risen Hirai ◽  
Akira Tanimura ◽  
Kei Yamamoto ◽  
...  
Keyword(s):  
Dna Repair ◽  
Enterococcus Faecium ◽  
High Dose ◽  
Dna Repair Genes ◽  
Repair Genes ◽  
Faecium Strain

scholarly journals Draft Genome Sequence of Probiotic Enterococcus faecium Strain L-3

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Alena Karaseva ◽  
Anna Tsapieva ◽  
Justin Pachebat ◽  
Alexander Suvorov
Keyword(s):  
Genome Sequence ◽  
Russian Federation ◽  
Enterococcus Faecium ◽  
Draft Genome ◽  
Bacteriocin Production ◽  
Draft Genome Sequence ◽  
Bacteriocin Producer ◽  
Probiotic Preparation ◽  
The Russian Federation ◽  
Faecium Strain

We report here the draft genome sequence of the bacteriocin producer Enterococcus faecium strain L-3, isolated from a probiotic preparation, Laminolact, which is widely used in the Russian Federation. The draft genome sequence is composed of 74 contigs for a total of 2,643,001 bp, with 2,646 coding genes. Five clusters for bacteriocin production were found.

Oral supplementation with l-glutamine alters gut microbiota of obese and overweight adults: A pilot study

Nutrition ◽  
2015 ◽  
Vol 31 (6) ◽  
pp. 884-889 ◽  
Author(s):  
Alessandra Zanin Zambom de Souza ◽  
Adriano Zanin Zambom ◽  
Kahlile Youssef Abboud ◽  
Sabrina Karen Reis ◽  
Fabiana Tannihão ◽  
...  
Keyword(s):  
Pilot Study ◽  
Gut Microbiota ◽  
Oral Supplementation ◽  
Overweight Adults
Sign in / Sign up

Export Citation Format

Share Document